You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company's stock will now trade on a split-adjusted basis on the Nasdaq after authorization for the split was approved by stockholders.
The company recently changed its name from Interpace Diagnostics as it expands its focus to include drug discovery and development services.
The disclosure comes less than a week after the company said that it was out of compliance with the Nasdaq's minimum shareholder equity requirement.
The cancer diagnostics developer said it was undertaking the reverse stock split in order to meet the Nasdaq's $1 minimum bid price requirement.
The company is taking the step to continue listing its shares on the Nasdaq, which had warned OpGen that did not meet a listing requirement calling for a minimum bid price of $1 per share.
OpGen had previously been warned by Nasdaq that it failed to meet listing requirements. Last week, the firm was told that it was ineligible for an extension to regain compliance.
The one-for-30 reverse split is intended to increase the price of the company's stock, enabling it to satisfy the Nasdaq's initial listing requirements.
The move is designed to help Rosetta regain compliance with the Nasdaq's $1 minimum bid requirement for continued listing.
Interpace hopes to keep its stock listed on the Nasdaq as a result of the reverse split.
The approval from the firm's shareholders and board comes after Great Basin moved its stock to the Over-the-Counter market in October.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.